SARS - Sareum to Present at BioTrinity 202030 Apr 2020 12:18
http://www.sareum.com/news/press-releases-and-news/2020/company-presentation-biotrinity/
Sareum Holdings plc (AIM:SAR), the specialist small molecule drug development business, announces that its CEO, Dr Tim Mitchell, will give a Company presentation at BioTrinity 2020, which will be delivered digitally from 28 April to 1 May 2020.
The presentation will provide an update of Sareum’s two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively. Dr Mitchell will also highlight the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from coronavirus and other viral infections.
Key cytokines that are found elevated in Covid-19 patients that have been admitted to intensive care include IL-2, IL-7, IL-10 and G-CSF*, all of which signal via JAK-family kinases. As the Company noted in its half yearly report, a paper in the European Respiratory Journal published in 2017** suggested that TYK2 inhibition might be effective in the treatment of influenza driven secondary bacterial pneumonia, which is potentially highly relevant against the backdrop of the Covid-19 pandemic. The Company also notes that it is preparing grant applications to fund studies to assess the potential use of its TYK2/JAK1 inhibitors to address this threat to global public health.
The presentation will be made through the BioTrinity virtual portal and will be available to registered participants during the conference and until at least 9 May 2020 - https://biotrinity.com/showcase.
A copy of the presentation will also be made available on Sareum’s website - www.sareum.co.uk.
BioTrinity is a long-running and highly regarded life sciences conference. It focuses on partnering, investment and collaboration, with the core delegate mix including early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
All aspects of the BioTrinity 2020 conference will be delivered in a digital format.
*C Huang et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (2020) Lancet 395(10223) 497-606)
**J Berg et al. TYK2 as a target for immune regulation in human viral/bacterial pneumonia. (2017) European Respiratory Journal 50: 1601953
Sign In
Follow the stocks
